Applications of 5-Iodo-1-Methyl-1H-Imidazole in Industrial Manufacturing

As the original manufacturer of 5-Iodo-1-Methyl-1H-Imidazole, we supply this specialty heterocyclic compound to serve as a critical building block in several high-value fine chemical and pharmaceutical industry segments. Below, we detail verified downstream applications and integration pathways meeting both regulatory and technical requirements across global markets.

1. Active Pharmaceutical Ingredient (API) Intermediate for Antiviral Agents

Pharmaceutical synthesis facilities utilize 5-Iodo-1-Methyl-1H-Imidazole as a targeted intermediate in route development for select antiviral small molecules. Its unique iodine-substituted imidazole ring structure enables regioselective cross-coupling and N-methyl incorporation steps, supporting optimized synthesis of nucleoside and non-nucleoside modulators. Process chemists require precise impurity profiles and tight control during transition-metal catalyzed transformations, with the material coursing through both batch and continuous stirred-tank reactors in GMP-compliant environments.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Directive (EudraLex) Part II
• USP/NF Monograph Guidance for Intermediates
• FDA 21 CFR 211 for finished pharmaceuticals

Typical usage ratio

• Between 0.7% and 4.5% by weight of total reaction input, adjusted based on the target API core and coupling partners; chemists select the minimal excess to drive complete conversion while limiting downstream purification workload.

Downstream process integration

• Introduced at the imidazole coupling or halogen exchange stage in API intermediate synthesis; inline LC-MS monitors the reaction endpoint and impurity carryover for batch release.

Final product types

• Bulk antiviral API intermediates (pre-purification)
• Branded and generic antiviral drug substances
• Terminally protected nucleoside analogs

2. Building Block for Pharmaceutical Analytical Reference Standards

Certified analytical laboratories procuring pharmaceutical impurity standards routinely employ 5-Iodo-1-Methyl-1H-Imidazole as a key reference precursor for method validation and specification development. Its reactivity profile simplifies isotopic labeling and side-chain modification for constructing high-purity reference compounds required to calibrate HPLC and LC-MS systems in both QC and regulatory submission batches.

Industry compliance standards

• ISO/IEC 17025 for testing and calibration laboratories
• USP General Chapter <1225> Validation of Compendial Procedures
• Ph. Eur. General Chapter 5.12 Reference Standards

Typical usage ratio

• Initial synthesis typically uses 1-2 molar equivalents per labeled or unlabeled analytical standard batch; adjustments depend on the planned substitution or label incorporation route.

Downstream process integration

• Installed as the core imidazole starting material in custom synthesis of trace-level analytical reference substances; highly controlled at each purification and labeling stage.

Final product types

• Certified impurity reference standards for pharmaceutical QC and lot-release
• Analytical calibrators for regulatory and in-house assay validation

3. Agrochemical Synthesis Intermediate for Crop Protection Actives

Producers of crop protection agents, particularly azole fungicide lines, select 5-Iodo-1-Methyl-1H-Imidazole for its direct involvement in core-ring constructing reactions and regioselective halogenation steps. Quality managers prioritize materials with controlled halogen content and consistent crystallinity to optimize yields during scale-up and minimize by-product formation, enabling the development of high-purity final actives suitable for multinational regulatory submission.

Industry compliance standards

• FAO/WHO Specification Guidelines for Pesticide Technical Materials
• ISO 9001:2015 for agrochemical production sites
• REACH Regulation (EC) No 1907/2006

Typical usage ratio

• Range from 0.8% to 3% by total synthesis mass, typically optimized through laboratory pre-formulation to balance raw material cost and conversion efficiency in halogen-bridging steps for azole ring formation.

Downstream process integration

• Introduced in the initial condensation or cyclization stage of imidazole-based fungicide core synthesis; followed by hydrolysis, purification, and formulation processing.

Final product types

• Technical-grade azole fungicides (e.g., prothioconazole intermediates)
• Formulable active ingredients for crop protection formulations

4. Intermediate in OLED (Organic Light-Emitting Diode) Material Synthesis

Electronic chemical manufacturers adopt 5-Iodo-1-Methyl-1H-Imidazole as a regioselective precursor in the synthesis of custom imidazole-based emitters and charge-transport molecules for advanced OLED device architectures. Process development chemists leverage its iodine site for precise cross-coupling and subsequent aromatic substitution, achieving target photophysical properties within strict tolerance levels for electronic grade organic materials.

Industry compliance standards

• IEC 62321 for hazardous substance analysis in electronics
• RoHS Directive 2011/65/EU on restricted substances
• ISO 14001:2015 for environmental management in material production

Typical usage ratio

• From 0.2% up to 2.5% by mass in precursor loading, scaled according to the specific charge-transport or emission compound design; adjustments accommodate the required molecular weight and purity profile for opto-electronic grade use.

Downstream process integration

• Charged into Suzuki or Buchwald–Hartwig coupling reactors for the functionalization of imidazole-based small molecule emitters; solvent and temperature strictly monitored to prevent iodine migration or oligomerization.

Final product types

• OLED emitter layers for display and lighting panels
• Organic charge-transport materials for semiconductor applications

5. Intermediate for Custom Chemical Synthesis in CRO/CDMO Operations

Contract research and custom manufacturing organizations (CRO/CDMO) specializing in structure-activity relationship (SAR) studies regularly deploy 5-Iodo-1-Methyl-1H-Imidazole for rapid analog generation and hit validation in medicinal chemistry pipelines. Its halogenated structure supports late-stage diversification by facilitating C–C and C–N bond formation under mild conditions.

Industry compliance standards

• ISO 9001:2015 for research chemical supply chains
• SQAS (Safety & Quality Assessment System) for specialty chemicals

Typical usage ratio

• Ranges from 0.5% to 6% depending on analog library scale, fragment add-on requirements, and targeted throughput per batch in medicinal chemistry campaigns.

Downstream process integration

• Employed in combinatorial synthesis arrays and late-stage diversification reactions; exposure managed in closed-vessel automated or manual setups with real-time tracking for impurity mapping.

Final product types

• SAR analog libraries for pharmaceutical research
• Lead molecule candidates for preclinical evaluation